A detailed history of Caxton Associates LP transactions in Catalent, Inc. stock. As of the latest transaction made, Caxton Associates LP holds 525,377 shares of CTLT stock, worth $32.3 Million. This represents 1.2% of its overall portfolio holdings.

Number of Shares
525,377
Previous 295,120 78.02%
Holding current value
$32.3 Million
Previous $16.6 Million 91.77%
% of portfolio
1.2%
Previous 0.57%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$56.16 - $60.96 $12.9 Million - $14 Million
230,257 Added 78.02%
525,377 $31.8 Million
Q2 2024

Aug 14, 2024

BUY
$53.58 - $57.02 $15.8 Million - $16.8 Million
295,120 New
295,120 $16.6 Million
Q4 2023

Feb 14, 2024

BUY
$32.18 - $46.57 $13.5 Million - $19.6 Million
420,000 New
420,000 $18.9 Million

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $11.1B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Caxton Associates LP Portfolio

Follow Caxton Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.